Quote:
Aβ catabolic pathway may offer an effective way to prevent as well as treat Alzheimer's disease
up-regulation of these Aβ-catabolic targets offers a novel, effective way to tackle Alzheimer's
.
This approach is gaining increasing attention and researchers are interested in finding pharmacological activators of these enzymes (NEP, IDE etc.).
In this context, it is interesting to note that a pre-approved drug for epilepsy, epilim (sodium valproate), has been shown to significantly elevate Neprilysin levels]
|
A? catabolism - An important Alzheimer's disease therapeutic target
The enzymes involved in Aβ degradation and clearance are- Neprilysin (NEP), . . .
It is a great pity that doctors are prevented from prescribing drugs for other than what they have been approved for. You would think they could be trusted, if not some sort of request or review process with health authorities should be in place. Many drug companies may not bother to try to have their drug approved for other disorders given the expense
And how are they going to know if their drug is good for something else unless Docs. begin to ask for it to be used in other ways and reporting their findings?
